A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer

Trial Profile

A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2017 This trial has been completed in Austria (End date:2017-07-08) as per European Clinical Trials Database record.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top